Cargando…

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer

Immunotherapy is a major breakthrough in the treatment of cancer in recent years. Immune checkpoint inhibitors (ICIs) including programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have been used for different histologic types of cancer including...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Wei, Zhao, Yunfeng, Du, He, Guo, Xuejun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416501/ https://www.ncbi.nlm.nih.gov/pubmed/34490104 http://dx.doi.org/10.3389/fonc.2021.704336

Ejemplares similares

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
por: Wang, Fuli, et al.
Publicado: (2023)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
por: He, Rui, et al.
Publicado: (2021)

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
por: Zhang, Wenxiang, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer
por: Johns, Andrew C, et al.
Publicado: (2023)

Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy
por: Kubo, Terufumi, et al.
Publicado: (2021)

Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis
por: Alifu, Muyesar, et al.
Publicado: (2023)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
por: Mussafi, Ofek, et al.
Publicado: (2022)

Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
por: Lee, Junghwa, et al.
Publicado: (2023)

Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Chen, Peixin, et al.
Publicado: (2021)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
por: Shang, Yufeng, et al.
Publicado: (2019)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
por: Hao, Yuxuan, et al.
Publicado: (2022)

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer
por: Gatti-Mays, Margaret E., et al.
Publicado: (2021)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

Growth hormone associated with treatment efficacy of immune checkpoint inhibitors in gastric cancer patients
por: Zhao, Yue, et al.
Publicado: (2022)

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
por: Lim, Sung Won, et al.
Publicado: (2019)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index
por: Zhang, Ting, et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
por: Yang, Fang, et al.
Publicado: (2022)

Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Cui, Yanan, et al.
Publicado: (2022)

Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer
por: Fang, Likui, et al.
Publicado: (2021)

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer
por: Zeng, Hao, et al.
Publicado: (2021)

Experiences of cancer immunotherapy with immune checkpoint inhibitors (ExCIm)—insights of people affected by cancer and healthcare professionals: a qualitative study protocol
por: Jennings, Stephen, et al.
Publicado: (2021)

An oxidative stress biomarkers predict prognosis in gastric cancer patients receiving immune checkpoint inhibitor
por: Deng, Guiming, et al.
Publicado: (2023)

On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
por: Kong, Benjamin Y., et al.
Publicado: (2019)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
por: Wang, Donghui, et al.
Publicado: (2021)

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
por: Sehgal, Kartik, et al.
Publicado: (2020)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Chai, Rong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hf3f6s3e7d4vs5ad9u72hvama0